RayzeBio Advances RYZ101 to Phase III Study in SSTR-Positive Neuroendocrine Tumors
The firm will compare its investigational radiopharmaceutical to standard therapies in patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors.
Bioinformatics Tool for Tracking Tumor-Immune Interactions Could Be Useful for Guiding Therapy
A map for discovering immune checkpoints and tumor process interactions is showing potential in identifying new drug targets and personalizing immunotherapy.
Bristol Myers Squibb Eyeing CLL, SLL as Additional Breyanzi Indications After Positive Readout
Around 18 percent of patients in a Phase I/II trial with aggressive, treatment-refractory forms of leukemia had complete responses on the CAR T-cell therapy.
Janssen Seeking European Approval for Carvykti as Earlier Refractory Multiple Myeloma Treatment
The firm submitted data from CARTITUDE-4, which showed the CAR T-cell therapy improved patients' progression-free survival compared to standard-of-care regimens.
Insilico Medicine to Begin Phase I USP1 Inhibitor Trial Following FDA IND Clearance
The firm's IND application was supported by preclinical studies showing activity of ISM3091 against BRCA-mutant and homologous repair-deficient cancers.